MS Specialist to Lead Trial of Temelimab in Progressing Disease Without Relapses
“It is evident that currently available disease modulatory therapies for MS exert very limited effects on the progressive aspect of MS, and that this phase starts early in the disease course. A role of pHERV-W Env in progressive disease worsening is supported by accumulating preclinical and clinical evidence,” Piehl said in the release.
https://multiplesclerosisnewstoday.c...le-sclerosis/?
“It is evident that currently available disease modulatory therapies for MS exert very limited effects on the progressive aspect of MS, and that this phase starts early in the disease course. A role of pHERV-W Env in progressive disease worsening is supported by accumulating preclinical and clinical evidence,” Piehl said in the release.
https://multiplesclerosisnewstoday.c...le-sclerosis/?
Comment